Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16020785 | 0.92 | XIAP (0.42) | XIAPNPY1RNMUR2F2CALCRL | |
| SCHEMBL17365609 | 0.83 | NMUR2 (0.44) | NPY1RNMUR2CALCRLNMUR1PRMT5 | |
| SCHEMBL9068934 | 0.82 | CALCRL (0.52) | NMUR2CALCRLPRMT5WDR77 | |
| SCHEMBL31497328 | 0.81 | KEAP1 (0.52) | NMUR2CALCRLPRMT5WDR77 | |
| SCHEMBL7401470 | 0.80 | CALCRL (0.48) | F2CALCRLCMA1 | |
| SCHEMBL7728874 | 0.80 | KEAP1 (0.43) | NPY1RNMUR2F2CALCRL | |
| SCHEMBL6524705 | 0.80 | BACE1 (0.48) | XIAPNMUR2CALCRLNTSR2NTSR1 | |
| SCHEMBL31497340 | 0.79 | KEAP1 (0.54) | NMUR2CALCRLNMUR1PRMT5WDR77 | |
| SCHEMBL9082723 | 0.79 | CALCRL (0.55) | NMUR2CALCRLPRMT5WDR77 | |
| SCHEMBL7735845 | 0.78 | CALCRL (0.45) | CALCRLPRMT5WDR77CMA1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256630-A1 | VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | INDI MOLECULAR, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256630-A1 | VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | FLT4, FLT1, KDR | XIAP 2440/4885NPY1R 2534/4885NMUR2 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.